Romero-Guevara Ricardo, Nicolaou Orthodoxia, Petracca Benedetta, Shaheed Sadr, Sutton Christopher, Frangou Eleni, Afami Marina, Kyriacou Kyriacos, Ioannides Adonis, Xinaris Christodoulos
Department of Basic and Clinical Sciences, University of Nicosia Medical School, Nicosia, Cyprus.
Department of Cancer Genetics, Therapeutics, and Ultrastructural Pathology, Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus.
Front Cell Dev Biol. 2023 Mar 2;11:1111424. doi: 10.3389/fcell.2023.1111424. eCollection 2023.
Alport syndrome (AS) is a rare disease characterized by defective glomerular basement membranes, caused by mutations in COL4A3, COL4A4, and COL4A5, which synthesize collagen type IV. Patients present with progressive proteinuria, hematuria and podocyte loss. There is currently no cure for Alport syndrome, and this is mainly due to its complex and variable pathogenesis, as well as the lack of models that can faithfully mimic the human phenotype. Here we have developed a novel human culture model of Alport syndrome and used it to study the effects of different mutations on podocyte development and biology. First, we established a differentiation protocol that allowed us to generate podocyte spheroids from patient-derived human induced pluripotent stem cells (hiPSCs). We have then carried out discovery proteomics and demonstrated that a total of 178 proteins were differentially expressed between Alport (AS1 and AS3) and control (LT) podocytes. GO analysis indicated alterations in several metabolic pathways, such as oxidative phosphorylation, RNA maturation, chromatin condensation, and proliferation. Although functional assays showed no changes in lactate production and mitochondrial potential compared to healthy controls, immunofluorescence and electron microscopy analysis showed key morphological changes related to the phenotypical maturation of Alport podocytes. Moreover, the studied mutations led to persistent proliferation, increased reactive oxygen species (ROS) production and the concomitant expression of peroxisome proliferator-activated receptors α and γ (PPARα and PPARγ) in podocytes. These data on patient-derived podocytes provide evidence that collagen mutations, in addition to playing a central role in the defective development of the glomerular filtration barrier, cause significant alterations in podocyte development and metabolism very early in development, even before the formation of the filtering apparatus. In conclusion, our study provides a new methodological platform for the differentiation of podocytes and to study human podocytopathies in a personalized manner, and reveals new insights into the etiopathogenesis and pathobiology of Alport syndrome.
奥尔波特综合征(AS)是一种罕见疾病,其特征为肾小球基底膜缺陷,由合成IV型胶原的COL4A3、COL4A4和COL4A5基因突变引起。患者表现为进行性蛋白尿、血尿和足细胞丢失。目前尚无治愈奥尔波特综合征的方法,这主要是由于其发病机制复杂且多变,以及缺乏能够忠实地模拟人类表型的模型。在此,我们开发了一种新型的奥尔波特综合征人类培养模型,并利用它来研究不同突变对足细胞发育和生物学特性的影响。首先,我们建立了一种分化方案,使我们能够从患者来源的人类诱导多能干细胞(hiPSC)生成足细胞球体。然后,我们进行了发现蛋白质组学研究,结果表明,在奥尔波特(AS1和AS3)足细胞与对照(LT)足细胞之间共有178种蛋白质差异表达。基因本体(GO)分析表明,氧化磷酸化、RNA成熟、染色质凝聚和增殖等几种代谢途径发生了改变。尽管功能分析显示与健康对照相比,乳酸产生和线粒体电位没有变化,但免疫荧光和电子显微镜分析显示,与奥尔波特足细胞的表型成熟相关的关键形态学变化。此外,所研究的突变导致足细胞持续增殖、活性氧(ROS)产生增加以及过氧化物酶体增殖物激活受体α和γ(PPARα和PPARγ)的伴随表达。这些来自患者来源足细胞的数据证明,胶原突变除了在肾小球滤过屏障的缺陷发育中起核心作用外,还在发育早期,甚至在滤过装置形成之前,就会导致足细胞发育和代谢的显著改变。总之,我们的研究为足细胞分化提供了一个新的方法平台,并以个性化方式研究人类足细胞病,揭示了奥尔波特综合征的病因发病机制和病理生物学的新见解。